• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief

N/A
N/A
Protected

Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Copied!
1
0
0

Pełen tekst

(1)

1

The Voice of the Editor-in-Chief

The progress of civilization, urbanization and relat- ed socio-economic changes lead to a change in the life- style of many societies, which, however, is not always beneficial in terms of health. The nutritional patterns are shifted towards increased use of highly-processed ready-to-eat food products characterized by high calo- rie content and high glycemic index but low nutritional value. Additionally, numerous facilities in everyday life favor the sedentary lifestyle without regular physical activity. These changes lead to an increased incidence of overweight and obesity and, as a consequence, to more and more often diagnosed type 2 diabetes. The basis of treatment of type 2 diabetes is behavioral modification which, however, is difficult to maintain and ineffective in a long-term perspective. Therefore, it must be based on broadly understood pharmaco- therapy. However, pharmacotherapy is also related

with some threats such as hypoglycemia, weight gain or complex therapeutic regimens. As a consequence, despite the availability of many groups of antidiabetic drugs, including those markedly reducing cardiovas- cular risk, most patients have insufficient metabolic control. Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk of development and progression of vascular complications and thus improve the quality of life of patients with diabetes.

I strongly encourage you to read this issue of our journal containing articles that discuss above- mentioned topics and indicate close associations between the achievements of basic science and clinical trials assessing the effectiveness and safety of new therapies.

Editor-in-Chief

Prof. Janusz Gumprecht

Dear Colleagues,

Cytaty

Powiązane dokumenty

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would